US2002042126A1PendingUtilityA1

Human integral membrane protein

Priority: Jul 14, 1997Filed: Mar 9, 1999Published: Apr 11, 2002
Est. expiryJul 14, 2017(expired)· nominal 20-yr term from priority
C07K 14/47A61K 38/00
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a new human integral membrane protein (NIMPH) and polynucleotides which identify and encode NIMPH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NIMPH.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A substantially purified human integral membrane protein comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.  
     
     
         2 . A substantially purified variant of human integral membrane protein having at least 90% amino acid identity to SEQ ID NO:1 and which retains at least one functional characteristic of human integral membrane protein.  
     
     
         3 . An isolated and purified polynucleotide sequence encoding the human integral membrane protein of  claim 1  or fragments or variants of said polynucleotide sequence.  
     
     
         4 . A composition comprising the polynucleotide sequence of  claim 3 .  
     
     
         5 . A polynucleotide sequence which hybridizes to the polynucleotide sequence of  claim 3 .  
     
     
         6 . A polynucleotide sequence which is complementary to the polynucleotide sequence of  claim 3  or fragments or variants thereof.  
     
     
         7 . An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or fragments or variants thereof.  
     
     
         8 . A polynucleotide sequence which is complementary to the polynucleotide sequence of  claim 7 .  
     
     
         9 . An expression vector containing at least a fragment of the polynucleotide sequence of  claim 3 .  
     
     
         10 . A host cell containing the vector of  claim 9 .  
     
     
         11 . A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, or a fragment thereof, the method comprising the steps of: 
 a) culturing the host cell of  claim 10  under conditions suitable for the expression of the polypeptide; and    b) recovering the polypeptide from the host cell culture.    
     
     
         12 . A pharmaceutical composition comprising a substantially purified human integral membrane protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.  
     
     
         13 . A purified antibody which specifically binds to the polypeptide of  claim 1 .  
     
     
         14 . A purified agonist of the polypeptide of  claim 1 .  
     
     
         15 . A purified antagonist of the polypeptide of  claim 1 .  
     
     
         16 . A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of  claim 12 .  
     
     
         17 . A method for treating a neuronal disorder comprising administering to a subject in need of such treatment an effective amount of the antagonist of  claim 15 .  
     
     
         18 . A method for treating an immunological disorder comprising administering to a subject in need of such treatment an effective amount of the antagonist of  claim 15   
     
     
         19 . A method for detecting a polynucleotide which encodes human integral membrane protein in a biological sample comprising the steps of: 
 a) hybridizing the polynucleotide of  claim 6  to nucleic acid material of a biological sample, thereby forming a hybridization complex; and    b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding human integral membrane protein in said biological sample.    
     
     
         20 . The method of  claim 19  wherein the nucleic acid material is amplified by the polymerase chain reaction prior to hybridization.

Join the waitlist — get patent alerts

Track US2002042126A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.